Denver, CO
Psychedelic Therapy clinics in Denver
Denver has 3 providers offering psychedelic therapy, with ketamine-assisted psychotherapy as the dominant nationwide option. Ketamine is FDA-approved as an anesthetic and Spravato (esketamine) is FDA-approved for treatment-resistant depression, while ketamine-assisted psychotherapy (KAP) is practiced off-label by licensed clinicians. Colorado's Proposition 122 (Natural Medicine Health Act) legalized regulated psilocybin services, with healing centers rolling out through 2025 and 2026. Colorado is one of only two states offering legal psilocybin pathways. Ketamine-assisted psychotherapy remains the most accessible medical option statewide. Denver clinics commonly pair ketamine infusions or IM injections with therapy sessions, typical packages run 2,500 to 6,000 dollars for a six-session protocol, and Spravato is covered by many insurers when criteria are met. Psilocybin and MDMA remain federally illegal, and the FDA issued a Complete Response Letter to Lykos Therapeutics in August 2024 for MDMA-assisted therapy for PTSD. A reputable Denver provider will screen for cardiovascular risk, psychiatric history, and concurrent medications before starting treatment.
Apogee Neuro
- Biofeedback Therapy
- Neurofeedback Therapy
- Psychedelic Therapy
- Erectile Dysfunction (ED) Treatment
Psychedelic Somatic Institute
- Ketamine Therapy
- Psychedelic Therapy
- Hormone Replacement Therapy (HRT)
Regulatory context
A note on Colorado's psychedelic therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
Colorado Proposition 122 / Natural Medicine Health Act (2022)
Decriminalized personal use of psilocybin, psilocyn, DMT, ibogaine, and mescaline (non-peyote) for adults 21+; authorized state-licensed Healing Centers for psilocybin-assisted therapy, with MDMA access permitted by state rule after June 2026. -
SB 23-290 Natural Medicine Regulation and Legalization
Implementing legislation establishing the Natural Medicine Division within DORA and the licensure framework for facilitators, healing centers, cultivators, and product manufacturers.
Colorado Healing Centers began licensing and operating in late 2024 and early 2025. The Colorado Department of Regulatory Agencies (DORA) Natural Medicine Division oversees facilitator licensure, healing center operations, testing, and track-and-trace. Federal law still classifies psilocybin as Schedule I, so DEA enforcement risk remains theoretical. The Colorado Medical Board regulates ketamine prescribing. Ryan Haight Act applies to telehealth ketamine.